Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,Immunology
Reference46 articles.
1. Appel H, Maier R, Wu P, Scheer R, Hempfing A, Kayser R, Sieper J (2011) Analysis of IL-17+ cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response. Arthr Res Ther 13(3):1–9
2. Babaie F, Hasankhani M, Mohammadi H, Safarzadeh E, Rezaiemanesh A, Salimi R, Babaloo Z (2018) The role of gut microbiota and IL-23/IL-17 pathway in ankylosing spondylitis immunopathogenesis: New insights and updates. Immunol Lett 196:52–62. https://doi.org/10.1016/j.imlet.2018.01.014
3. Baeten D, Baraliakos X, Braun J, Sieper J, Emery P, Van der Heijde D, Wordsworth P (2013) Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. The Lancet 382(9906):1705–1713
4. Baeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P, Andersson M (2015) Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N Engl J Med 373(26):2534–2548
5. Baraliakos X, Kivitz AJ, Deodhar AA, Braun J, Wei JC, Delicha EM (2018) Long-term effects of interleukin-17A inhibition with secukinumab in active ankylosing spondylitis: 3-year efficacy and safety results from an extension of the Phase 3 MEASURE 1 trial. Clin Exp Rheumatol 36(1):50–55
Cited by
21 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献